Hims & Hers Health hiked its full-year revenue guidance well above Wall Street targets, even as a wider-than-expected quarterly loss pushed shares lower in late trading Monday.

The telehealth company forecast revenue between $3.1 billion and $3.3 billion for the full year, up from a prior range of $2.8 billion to $3 billion and ahead of Wall Street's call for $2.93 billion. Management's current-quarter guidance for $880 million to $900 million in revenue also beat analysts' projections for $792.2 million.

Second-quarter earnings themselves were mixed. Hims reported second-quarter revenue of $753.2 million, comfortably beating the FactSet consensus estimate of $698.9 million. However, the company also posted a loss of 37 cents a share, wider than the 5-cent loss analysts had anticipated.

Hims stock tumbled 4.1% in after-hours trading following the report. Shares ended Monday's session up 0.6%.

Commentary in the report centered heavily on artificial intelligence. CEO Andrew Dudum touted the company's new "doctor-led AI clinical engine" in a statement, saying it was helping Hims "rebuild the consumer health experience from the ground up."

Chief Financial Officer Yemi Okupe was similarly upbeat, attributing the guidance hike to AI-driven operational efficiencies and growing international momentum following the acquisition of Australian telehealth firm Eucalyptus.

Hims is navigating a strategic transition following the wind-down of its GLP-1 compounding operations -- a business that fueled its rise during a widespread shortage of medications like Wegovy and Zepbound.

In May 2024, Hims began offering non-branded semaglutide, the active ingredient in Novo Nordisk's Wegovy. The company took advantage of a legal framework allowing it to circumvent Food and Drug Administration approval for its products.

Novo agreed in March to drop a patent infringement lawsuit in exchange for the telehealth provider's commitment to sell branded Ozempic and Wegovy through its online pharmacy. Hims ultimately agreed to halt production of its own compounded GLP-1 drugs and sell a range of FDA-approved products instead.

While leadership has repeatedly asserted that compounded GLP-1s composed a fraction of the business, Hims shares nevertheless have come under pressure.

The company said on Monday that it expects to incur ongoing restructuring charges linked to a shift in its U.S. weight-loss segment, reflecting a move toward branded GLP-1s and more limited compounded offerings.